Cargando…

Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma

Single nucleotide polymorphisms (SNPs) of vascular endothelial growth factor receptor (VEGFR) may have effects on the MAPK/ERK/STAT3 signaling pathway, and the resulting phenotypes may influence the response to sunitinib-targeted therapy for renal cell carcinoma. In order to test this hypothesis pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Rui, Wang, Xiaojie, Li, Wei, Shou, Tao, Zhou, Likun, Li, Yunfen, Bai, Ming, Pei, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244963/ https://www.ncbi.nlm.nih.gov/pubmed/28123542 http://dx.doi.org/10.3892/ol.2016.5396

Ejemplares similares

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
por: Miao, Chenkui, et al.
Publicado: (2017)

Association of the VEGFR2 single nucleotide polymorphism rs2305948 with glioma risk
por: Sun, Shushu, et al.
Publicado: (2022)

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
por: Liu, Xiaoyan, et al.
Publicado: (2016)

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
por: Ganapathi, Ram N, et al.
Publicado: (2011)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
por: Chen, Ying-Shou, et al.
Publicado: (2009)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
por: Sun, Fengjun, et al.
Publicado: (2021)

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2014)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?
por: Bresciani, Giulia, et al.
Publicado: (2019)

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
por: Hansson, E K, et al.
Publicado: (2013)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

The Association between VEGFR Gene Polymorphisms and Stroke: A Meta-Analysis
por: Qiu, Shi, et al.
Publicado: (2016)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
por: Al-Lamki, Rafia S., et al.
Publicado: (2020)

Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports
por: Prochilo, Tiziana, et al.
Publicado: (2013)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
por: Wu, Zeshen, et al.
Publicado: (2022)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Impact of single nucleotide polymorphisms in the VEGFR2 gene on endothelial cell activation under non-uniform shear stress
por: Schacher, Nora M., et al.
Publicado: (2019)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
por: Hwang, Eugene, et al.
Publicado: (2010)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma
por: Chu, Ying-Hsia, et al.
Publicado: (2015)

Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis
por: Liu, Xiu-Lan, et al.
Publicado: (2020)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis
por: Butz, Henriett, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fpv7llqfpm1u6o4n95hrdm3meq